These questions and answers (Q&As) are based on the most recent interim recommendations from the WHO Strategic Advisory Group of Experts on Immunization (SAGE) for COVID-19 vaccines that have been approved by WHO under Emergency Use Listing (EUL)a as of 15 February 2022:
- Pfizer–BioNTech BNT162b2
- Moderna mRNA-1273
- AstraZeneca AZD1222 Vaxzevria™, SII COVISHIELD™ ChAdOx1-S [recombinant]
- Janssen Ad26.COV2.S
- Sinopharm BIBP
- Bharat Biotech BBV152 COVAXIN®
- Novavax NVX-Co2373
The Q&As are intended to provide answers to health providers and the public on COVID-19 vaccination during pregnancy. Q&As related to COVID-19 vaccines and breastfeeding can be found at the following link: FREQUENTLY ASKED QUESTIONS: COVID-19 vaccines and breastfeeding based on WHO interim recommendations.
This document uses the term ‘pregnant women’. Although the majority of people who are or can get pregnant are cisgender women, who were born and identify as female, these Q&As are also relevant to the experiences of transgender men and other gender diverse people who may have the capacity to become pregnant.